Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Perrigo receives US approval for clobetasol propionate foam
The product is a topical corticosteroid indicated for the treatment of moderate to severe dermatosis of the scalp. As the first filer, Perrigo will be eligible for 180
The product is a topical corticosteroid indicated for the treatment of moderate to severe dermatosis of the scalp. As the first filer, Perrigo will be eligible for 180
Ubiquinol is the active antioxidant form of Coenzyme Q10 (CoQ10). In the first clinical trial evaluating ubiquinol effects on late-stage congestive heart failure, researchers found that critically ill
The appellate court found that Stryker’s accused device contains precisely the same structure shown in TriMed’s patent. TriMed is seeking a permanent injunction of Stryker from further use
Tobramycin injection is an antibiotic and is indicated for the use in treating or preventing infections that are proven or strongly suspected to be caused by susceptible bacteria.
The US Patent Office has issued notices of intent to Issue Ex Parte Reexamination Certificates for US patents which claim preparations of, respectively, primate and human embryonic stem
Third Wave’s 14-type high-risk human papillomavirus (HPV) test demonstrated a negative predictive value greater than the study’s 99% goal. Negative predictive value is the probability that there is
After reviewing data on the safety and efficacy of the medication, the committee unanimously recommended approval of the company’s application for marketing. The FDA is not bound by
In particular the deal will directly enhance product development work for Clostridium difficile, E.coli and immune deficiency related opportunistic infections. The licensed technologies are all related to the
As part of the investigational new drug application (IND) submission, Arisaph has completed comprehensive nonclinical safety pharmacology and toxicology studies, including 28 day toxicology studies in rats and
The contract is for a period of five years with anticipated revenues of approximately $95 million. Under this agreement, Cognizant will provide a broad spectrum of centralized data